Exploring Extravascular Defibrillation Devices for Ventricular Tachycardia Management

This case explores the puzzling presentation of exercise-induced ventricular tachycardia in a young, otherwise healthy male who suffered recurrent out-of-hospital cardiac arrests. With no traditional risk factors and an unremarkable ischemic workup, the challenge lay in uncovering the underlying cause of his malignant arrhythmias. Electrophysiology studies and advanced imaging played a pivotal role in systematically narrowing the differentials, revealing an unexpected arrhythmogenic substrate. This episode delves into the diagnostic dilemma, the role of EP testing, and the critical decision-making surrounding ICD placement in a patient with a concealed but life-threatening condition. 

“To study the phenomena of disease without books is to sail an uncharted sea, while to study books without patients is not to go to sea at all.” – Sir William Osler. CardioNerds thank the patients and their loved ones whose stories teach us the Art of Medicine and support our Mission to Democratize Cardiovascular Medicine.

Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.

US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here.

Pearls- Malignant Ventricular Arrhythmias

This case highlights the challenges and importance of diagnosing and managing ventricular arrhythmias in young, seemingly healthy individuals. Here are five key takeaways from the episode: 

1. Electrophysiology (EP) studies play a crucial role in identifying arrhythmogenic substrates in patients with exercise-induced ventricular tachycardia (VT) without obvious structural heart disease. In this case, substrate mapping revealed late abnormal ventricular afterdepolarizations in the basal inferior left ventricle, providing valuable insights into the underlying mechanism. 

2. Cardiac MRI can be a powerful tool for detecting subtle myocardial abnormalities. The subepicardial late gadolinium enhancement (LGE) in the lateral and inferior LV walls suggested an underlying myocardial process, even when other imaging modalities appeared normal. 

3. The VT morphology can provide clues about the underlying mechanism. In this case, the right bundle branch block pattern with a northwest axis and shifting exit sites pointed towards a scar-mediated mechanism rather than a channelopathy or idiopathic VT. 

4. Implantable cardioverter-defibrillator (ICD) placement is crucial for secondary prevention of sudden cardiac death (SCD) in patients with malignant ventricular arrhythmias, even in young individuals. The patient’s initial deferral of ICD implantation highlights the importance of shared decision-making and patient education in these complex cases. 

5. “Scar-mediated VT introduces the risk of new arrhythmogenic substrates over time, reinforcing the need for ICD therapy even when catheter ablation is considered.” This pearl emphasizes the dynamic nature of the arrhythmogenic substrate and the importance of long-term risk mitigation strategies. 

Notes – Malignant Ventricular Arrhythmias

Notes were drafted by Juma Bin Firos. 

1. What underlying pathologies cause ventricular arrhythmias in young patients without overt structural heart disease?

Myocardial fibrosis:

• Detected via late gadolinium enhancement (LGE) on cardiac MRI
• Present in 38% of nonischemic cardiomyopathy cases
• Increases sudden cardiac death (SCD) risk 5-fold
• Often localized to subepicardial regions, particularly in the inferolateral left ventricle (LV)
• May precede overt systolic dysfunction by years

Subclinical cardiomyopathy:

• 67% of young VT patients show subtle cardiac dysfunction
• Suggests VT may be the first manifestation of cardiomyopathy
• Can include early-stage genetic cardiomyopathies (e.g., ARVC, LMNA mutations)
• Often associated with preserved ejection fraction (EF >50%)

Arrhythmogenic substrate:

• EP studies localize re-entry circuits to specific regions:
  • Basal inferior LV near the mitral annulus (as in this case)
  • Right ventricular outflow tract (RVOT) in idiopathic VT
  • Papillary muscles or fascicular regions
• Substrate can exist even with normal EF and no visible structural abnormalities on echocardiography

Channelopathies:

• Long QT syndrome (LQTS): QTc >460ms in males, >470ms in females
• Brugada syndrome: Coved ST elevation in V1-V3
• Catecholaminergic polymorphic VT (CPVT): Normal resting ECG, bidirectional VT with exercise
• Short QT syndrome: QTc <330ms

Inflammatory conditions:

• Myocarditis: Can cause transient or persistent arrhythmogenic substrate
• Cardiac sarcoidosis: Patchy inflammation and fibrosis, often affecting the septum

2. How do electrophysiology studies differentiate scar-mediated VT from channelopathies?

Substrate mapping:

• Identifies late abnormal potentials (LAPs) with 92% specificity for re-entry circuits
• Utilizes multi-electrode catheters (e.g., Penta Ray) for high-density mapping
• LAPs indicate slow conduction through fibrotic tissue, key for re-entry
• Absent in purely electrical disorders like channelopathies

Inducibility:

• Programmed electrical stimulation (PES) protocols:
• Up to triple extra stimuli at multiple sites (RV apex, RVOT, LV)
• Burst pacing at cycle lengths down to 200-250ms
• Scar-mediated VT is often inducible with aggressive stimulation
• Polymorphic VT/VF induction suggests a structural substrate
• Channelopathies like Catecholaminergic polymorphic ventricular tachycardia CPVT) typically requires isoproterenol or exercise for induction

VT morphology analysis:

• Right bundle branch block (RBBB) + northwest axis localizes to LV basal inferior wall
• Left bundle branch block (LBBB) + inferior axis suggests RVOT origin
• Fascicular VT: RBBB + left anterior or posterior fascicular block pattern
• Papillary muscle VT: RBBB or LBBB with variable axis

Entrainment mapping:

• Performed during sustained monomorphic VT
• Post-pacing interval minus tachycardia cycle length (PPI-TCL) <30ms indicates critical isthmus
• Not applicable to polymorphic VT or channelopathies

Electroanatomic voltage mapping:

• Low voltage areas (<1.5mV bipolar) indicate scar tissue
• Normal voltage throughout suggests functional (non-scar) VT mechanism

3. What are key management considerations for recurrent VT/VF in young patients?

• ICD for secondary prevention:
  • Class I indication after cardiac arrest or sustained VT without a reversible cause
  • Reduces mortality from 13% (8-year untreated) to <5%, especially with LGE present
• Device selection:
  • Single-chamber ICD if no pacing indication
  • Subcutaneous ICD (S-ICD) in young patients to avoid transvenous lead complications
  • Consider cardiac resynchronization therapy defibrillator (CRT-D) if LBBB or wide QRS
• LifeVest limitations:
  • Bridges ≤3 months; not a long-term solution
  • Recurrent arrests double mortality vs. prompt ICD implantation
  • Compliance issues: must be worn consistently to be effective
• Oral antiarrhythmic medications:
  • Amiodarone:
    • Effective for acute VT suppression
    • Long-term use limited by side effects (thyroid, liver, pulmonary toxicity)
  • Beta-blockers: First line for most VT/VF, especially exercise-induced
  • Sotalol: Alternative for those with preserved LV function
  • Mexiletine: Adjunct for frequent ICD shocks, especially with LQT3
• Catheter ablation:
  • Consider early in the course for recurrent ICD shocks
  • Success rates 60-80% for scar-related VT
  • May reduce ICD shocks and improve quality of life
  • Limitations: deep intramural or epicardial substrates may require specialized approaches
• Lifestyle modifications:
  • Exercise restrictions: Avoid high-intensity activities that trigger arrhythmias
  • Stress management: Consider cognitive behavioral therapy or mindfulness training
  • Avoidance of QT-prolonging medications in LQTS patients
• Genetic testing and family screening:
  • Recommended for suspected inherited arrhythmia syndromes
  • Can guide management and risk stratification for family members

4. Why does exercise exacerbate arrhythmia risk in these patients?

• Sympathetic surge:
  • Increases myocardial oxygen demand
  • Enhances automaticity and triggered activity
  • Can unmask concealed conduction abnormalities
• Hemodynamic changes:
  • Increased preload and afterload stress fibrotic regions
  • Volume shifts may alter electrolyte concentrations locally
• Metabolic factors:
  • Lactic acid accumulation can promote ectopic beats
  • Catecholamine release exacerbates ion channel dysfunction in channelopathies
• Exercise-induced VT/VF correlates with 8× higher SCD risk vs. rest-onset arrhythmias:
  • Warrants activity restrictions tailored to individual risk profile
  • May indicate more malignant substrate or advanced disease process
• Treadmill testing:
  • Should guide therapy in asymptomatic patients with exercise-related VT
    • Protocols:
    • Bruce protocol for general assessment
    • Modified protocols (e.g., longer stages) for specific arrhythmia provocation
  • Endpoints:
    • Induction of sustained VT/VF
    • Achieving target heart rate (85% of age-predicted maximum)
    • Development of concerning symptoms (pre-syncope, chest pain)
• Cardiac rehabilitation:
• Supervised exercise programs can improve outcomes
• Gradual increase in intensity with continuous monitoring
• Helps define safe exercise thresholds for patients

5. How does LGE on cardiac MRI refine risk stratification?

Late gadolinium enhancement (LGE) on cardiac MRI acts like a “scar map” of the heart, revealing areas of damaged or fibrotic tissue. These scars create electrical instability, increasing the risk of dangerous heart rhythms and sudden cardiac death (SCD). Here’s how LGE refines risk assessment:

1. Predicting Sudden Cardiac Death (SCD)

• Major risk multiplier:
  • Patients with LGE have 4.3× higher odds of life-threatening arrhythmia, regardless of their heart’s pumping ability (ejection fraction, EF).
  • For every 1% increase in scar size (as % of heart muscle), SCD risk rises by 15%.
• Thresholds matter:
  • In hypertrophic cardiomyopathy (HCM), LGE covering ≥5% of the heart muscle adds critical risk stratification, even in patients not initially flagged as high-risk by guidelines.
  • Larger scars (≥10-15%) correlate with dramatically higher SCD risk, especially in HCM.

2. Mortality Signals

• Annual death rates:
  • LGE+ patients: 4.7% annual mortality (similar to ischemic heart disease).
  • LGE− patients: 1.7% annual mortality.
• Patterns and locations:
  • Midwall scars (e.g., in dilated cardiomyopathy): 4.6× higher risk of SCD.
  • Inferolateral scars (common in cardiac sarcoidosis): Linked to frequent ventricular tachycardia (VT).

3. Quantifying Scars: Methods Matter

• Full Width at Half Maximum (FWHM):
  • Most reproducible method for measuring scar size.
  • Reduces overestimation compared to other techniques.
• Standard Deviation (SD) thresholds:
  • 5-SD method: Widely used but may overestimate scar size.
  • 6-SD method: Best studied; 10% LGE is the optimal cutoff for predicting SCD in HCM.
• Dark-blood vs. bright-blood imaging:
  • Dark-blood LGE improves scar visualization in ischemic heart disease but performs similarly to bright-blood LGE in non-ischemic conditions.

4. Guideline Gaps and Solutions

• Current ICD criteria fall short:
  • Guidelines focus on EF ≤35%, missing high-risk patients with EF >35% but significant LGE.
  • Example: A patient with EF 45% and 12% LGE has higher SCD risk than many with EF ≤35%.
• Emerging recommendations:
  • Use LGE to guide ICD decisions in the “grey zone” (EF 36-50%).
  • The 2022 ESC HCM model now integrates LGE for better risk prediction.

5. Tracking Changes Over Time

• Serial imaging:
  • Repeat MRIs every 1-2 years monitor scar progression.
  • Example: If LGE grows from 8% to 14%, ICD may be warranted even if EF remains normal.

6. Limitations

• Not all scars are equal:
  • Ischemic scars (from blocked arteries) vs. non-ischemic scars (e.g., HCM) carry different risks.
• Technical challenges:
  • Labs use different methods (e.g., FWHM vs. SD), causing variability in measurements.
• Contraindications:
  • Severe kidney disease (risk of gadolinium toxicity) or implanted devices (e.g., older pacemakers) may limit MRI use.

References – Malignant Ventricular Arrhythmias

Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., … & Page, R. L. (2018). 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 72(14), e91-e220. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549 

Di Marco, A., Anguera, I., Schmitt, M., Klem, I., Neilan, T. G., White, J. A., … & Cequier, A. (2017). Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC: Heart Failure, 5(1), 28-38. https://www.sciencedirect.com/science/article/pii/S2213177916305698?via%3Dihub 

Kuruvilla, S., Adenaw, N., Katwal, A. B., Lipinski, M. J., Kramer, C. M., & Salerno, M. (2014). Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circulation: Cardiovascular Imaging, 7(2), 250-258. 

https://pubmed.ncbi.nlm.nih.gov/24363358

Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., … & Prasad, S. K. (2013). Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. Jama, 309(9), 896-908. https://jamanetwork.com/journals/jama/fullarticle/1660382 

Piers, S. R., Tao, Q., van Huls van Taxis, C. F., Schalij, M. J., van der Geest, R. J., & Zeppenfeld, K. (2013). Contrast-enhanced MRI–derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circulation: Arrhythmia and Electrophysiology, 6(5), 875-883. https://pubmed.ncbi.nlm.nih.gov/24036134/ 

Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., … & Van Veldhuisen, D. J. (2015). ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 36(41), 2793-2867. https://pubmed.ncbi.nlm.nih.gov/26320108/ 

Wang, J., Yang, S., Ma, X., Zhao, K., Yang, K., Yu, S., … & Zhao, S. (2023). Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines. European heart journal, 44(45), 4781-4792. https://pubmed.ncbi.nlm.nih.gov/37795986/ 

Kiaos, A., Daskalopoulos, G. N., Kamperidis, V., Ziakas, A., Efthimiadis, G., & Karamitsos, T. D. (2024). Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis. Cardiovascular Imaging, 17(5), 489-497. https://pubmed.ncbi.nlm.nih.gov/37795986/ 

Case Media